Trial Profile
A Phase 1 Study to Evaluate the Pharmacokinetics of ITCA 650 in Subjects With Mild and Moderate Renal Impairment Compared to the Pharmacokinetics of Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Intarcia Therapeutics
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 30 Jul 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 22 Dec 2014 New trial record